Engineered Antigens Inc.

University of Toronto

National Research Council of Canada

Scott D Gray-Owen

Anthony Bernard Schryvers

Trevor F Moraes

Andrew Judd

Christine Chieh-Lin Lai

Yogesh Hooda

Andrew Cox

Janelle Sauvageau

Xinyi Guo

Ryan Gaudet

Rebecca Malott

Novel methods for exporting target proteins from the cytosol to the extracellular surface of bacterial cells are provided. The methods are useful in that they permit the preparation of vaccines for the prevention of bacterial infectious diseases.

SLAM polynucleotides and polypeptides and uses thereof

Phosphorylated heptose compounds are useful in modulating an immune response in a subject. Also, the compounds are useful as adjuvants.

Use of phosphorylated heptose compounds

Heptose-1-monophosphate-7-derivatives are modifiable immunomodulators that can be used to prepare clinically active conjugate compounds. Such conjugate compounds are useful in modulating an immune response in a subject.

D-glycero-B-D-heptose 1-phosphate (HMP) conjugates and use for targeted immune modulation

The present disclosure relates to methods for exporting target proteins (e.g., surface lipoproteins) from the cytosol to the extracellular surface of bacterial cells using surface lipoprotein assembly modulator (SLAM) polypeptides. The use of SLAM polypeptides in a method of preparing vaccines useful in the prevention of bacterial infectious diseases is also taught.

Novel methods and uses for modulating immune responses are provided. The methods and uses involve the use of a TIFA activator such heptose-1,7-5 bisphosphate or an analog or derivative thereof. The methods may be used to activate, inhibit or otherwise modify an immune response so as to either prevent or treat infectious or inflammatory diseases or cancer. Also provided are methods to identify compounds capable of modulating immune responses.

Methods of modulating immune system responses

The disclosure provides immunogenic compositions comprising a polypeptide comprising a C-lobe domain or an N-lobe domain of a HIBP surface receptor protein obtainable from or obtained from a Gram-negative bacterial species. The HIBP surface receptor proteins have been modified in such a manner that they are unable to bind host iron binding protein. Methods of making and using these immunogenic positions to prepare animal and human vaccines are also provided.

Growing community of inventors

Oakville, Canada

Scott D Gray-Owen